We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Molecular Pathway Controls Metastasis in Mouse Melanoma Model

By LabMedica International staff writers
Posted on 05 Jan 2015
Cancer researchers have found that the protein Chi3l1 (Chitinase 3-like-1) stimulates formation of metastases in a mouse model under the regulatory influence of the protein semaphorin 7a (Sema7a) and its receptors.

The CHI3L1 gene encodes a glycoprotein member of the glycosyl hydrolase 18 family. More...
The protein product lacks chitinase activity and is secreted by activated macrophages, chondrocytes, neutrophils, and synovial cells. The protein is thought to play a role in the process of inflammation and tissue remodeling. Semaphorins are a class of secreted and membrane proteins that act as axonal growth cone guidance molecules. They primarily act as short-range inhibitory signals and signal through multimeric receptor complexes with plexins being the major class of semaphorin receptor proteins.

Chi3l1 was found in earlier studies to be induced in cancers where it indicated a poor prognosis. However, it has not been known whether it actually contributed to cancer progression. To address this gap in knowledge investigators at Brown University (Providence, RI, USA) examined the production of Chi3l1 in a mouse model of melanoma lung metastases.

They reported in the December 15, 2014, online edition of the journal Cancer Research that Chi3l1 levels were elevated in mice, as in humans, with progressing cancer. Chi3l1 was induced during pulmonary melanoma metastasis, and this induction was regulated by Sema7a, interacting in stimulatory or inhibitory ways with its beta-1 integrin or Plexin C1 receptors, respectively. In mouse strains with genetic deletions of CHI3L1 or Sema7a, there was a significant reduction in pulmonary metastasis. Furthermore, antiserum raised against Chi3l1 or Sema7a induced the same reduction in metastasis as was produced by genetic deletions. Melanoma lung metastasis was also decreased in the absence of the cytokine IL-13Ralpha2, a recently identified receptor for Chi3l1, consistent with a key role for Chi3l1 in melanoma spread.

"We think everybody has Chitinase 3-like-1 (Chi3l1) in them because it plays a major role in our ability to fight off infections," said senior author Dr. Jack A. Elias, professor of medicine and biological sciences at Brown University. "But one of the things this paper shows is that inducing this molecule seems to be very important in the ability of tumors to spread. That leads us to believe this may be a fundamental pathway in the generation of metastases. We know what molecules are involved in the triggering of this. We do not know where they are and which of them are on the tumor and which are in the normal tissue around the tumor."

Related Links:

Brown University



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.